#ComparativeEffectiveness #RealWorldData #RWE #HealthcareAnalytics #DataScience #EvidenceBasedMedicine To view or add a comment, sign in New clinical data strengthens Collavant n2s role in joint health innovation Bioiberica has unveiled fresh clinical findings showing that just 40 mg/day of its native type II collagen, Collavant n2, can support articular cartilage health in healthy individuals experiencing activity-related joint discomfort a first for this ingredient
Speaking over the companys earnings call, Srinivas Sadu, Executive Chairman Gland Pharma, said, Our GLP-1 strategy gained momentum last quarter and and this quarter th drug was launched in UK and Australia. We are aggressively increasing our GLP-1/Pen/cartridge capacity from 40 million to 140 million units, and the battery acceptance test (BAT) scheduled to be completed by September 2025, the executive chairman added
That said, any GLP-1 therapy initiation in a breast cancer survivor should involve communication between your oncology team and your primary care provider
Is your business being affected by GLP-1 medications
Weibull distribution modeling ( = 0.59, 95% CI 0.580.61) indicated these NAEs are likely to occur during initial treatment phases (Table 2, Fig
